Biocon Ltd is quoting at Rs 397.1, up 1.76% on the day as on 12:49 IST on the NSE. The stock is up 36.81% in last one year as compared to a 7.61% gain in NIFTY and a 18.78% gain in the Nifty Pharma ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the US, including Bevacizumab in oncology, insulin Aspart in diabetes, and ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Paradeep Phosphates has signed a memorandum of understanding with the Odisha government for an investment of Rs 4,000 crore, ...

Shares of Biocon Ltd closed slightly higher at ₹357.15 on the BSE today, up 0.44% or ₹1.55, ahead of the earnings ...

Biocon Ltd.'s disappointing Q3FY25 performance was largely due to exceptional items, with adjusted net profit standing at Rs 13 crore, and revenue growth of 7% on a like-for-like basis.

In this highlight video from the second episode of PwC Presents BT MindRush Pods, Siddharth Zarabi, Editor, Business Today, and Sanjeev Krishan, Chairperson, PwC in India, sit down with Kiran Mazumdar ...

The Competition Commission of India (CCI) recently imposed a penalty of ₹40 lakh on Goldman Sachs (India) Alternative Investment Manage ...

Biocon Ltd share price was up by 1.72% from the previous closing price of ₹390.25. Who are peers of Biocon Ltd? The peers of Biocon Ltd are Sun Pharmaceuticals Industries Ltd, Divis Laboratories ...

Biocon Biologics CEO discusses revenue growth, market diversification, debt strategy, and impact of US pro-localisation policy.